Patents Represented by Attorney Harry E. Westlake, Jr.
  • Patent number: 4215221
    Abstract: A process for preparing .alpha.-fluoromethyl amino acids from corresponding .alpha.-hydroxymethyl amino acids is disclosed. The process utilizes SF.sub.4 and BF.sub.3 or AlCl.sub.3 in HF to effect the fluorination.
    Type: Grant
    Filed: September 1, 1978
    Date of Patent: July 29, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Janos Kollonitsch, Stephen Marburg
  • Patent number: 4215110
    Abstract: A method of treating hypertension by administration, to hypertensive patients, of an anti-hypertensive amount of certain tripeptides, is disclosed.
    Type: Grant
    Filed: September 22, 1978
    Date of Patent: July 29, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Victor J. Lotti, Clement A. Stone
  • Patent number: 4210653
    Abstract: Pyridyloxypropanolamines, their preparation and use as antihypertensive agents is disclosed.
    Type: Grant
    Filed: June 27, 1978
    Date of Patent: July 1, 1980
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David E. McClure
  • Patent number: 4208413
    Abstract: The case involves novel N-pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same. The compounds are excellent eukalemic agents possessing diuretic and natriuretic properties.
    Type: Grant
    Filed: December 4, 1978
    Date of Patent: June 17, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Otto W. Woltersdorf, Jr.
  • Patent number: 4208416
    Abstract: N-Aralkylamino-OR-propoxycyanopyridines having pharmacological activity are disclosed.
    Type: Grant
    Filed: June 27, 1978
    Date of Patent: June 17, 1980
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Patent number: 4207329
    Abstract: Novel derivatives of glycolic and glyoxylic acid are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate urolithiasis (calcium oxalate kidney and bladder stone disease).
    Type: Grant
    Filed: October 11, 1978
    Date of Patent: June 10, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Haydn W. R. Williams, Edward J. Cragoe, Jr., Clarence S. Rooney
  • Patent number: 4206295
    Abstract: Novel polymers having a linear backbone which is free from both branching and cross-linking, comprising quaternized nitrogen atoms linked to each other through trimethylene groups. By the term "linear backbone" is meant that the polymer has only acyclic groups, i.e. trimethylene, linking the nitrogen atoms in a single continuous chain; the polymer is free from "branching" when it has no repeating monomer units extending from the polymer backbone; and it is free from "cross-linking" when there is no joining of two linear backbones. These polymers are useful as antimicrobials, flocculating agents, antistatic agents, electroconductive agents for coating paper, chelating agents and bile acid binding agents, as well as in similar applications where their high charge to weight ratio and fully accessible nitrogen atoms can be employed. The polymers are obtained by the polymerization of dihydro-oxazine, reductive alkylation of the resulting polymer, followed by quaternization.
    Type: Grant
    Filed: April 11, 1979
    Date of Patent: June 3, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Arthur F. Wagner, Nathaniel Grier, Tsung-Ying Shen
  • Patent number: 4205064
    Abstract: Novel polymers having a linear backbone which is free from both branching and cross-linking, comprising quaternized nitrogen atoms linked to each other through trimethylene groups. By the term "linear backbone" is meant that the polymer has only acyclic groups, i. e. trimethylene, linking the nitrogen atoms in a single continuous chain; the polymer is free from "branching" when it has no repeating monomer units extending from the polymer backbone; and it is free from "cross-linking" when there is no joining of two linear backbones. These polymers are useful as antimicrobials, flocculating agents, antistatic agents, electroconductive agents for coating paper, chelating agents and bile acid binding agents, as well as in similar applications where their high charge to weight ratio and fully accessible nitrogen atoms can be employed. The polymers are obtained by the polymerization of dihydro-oxazine, reductive alkylation of the resulting polymer, followed by quaternization.
    Type: Grant
    Filed: April 11, 1979
    Date of Patent: May 27, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Arthur F. Wagner, Nathaniel Grier, Tsung-Ting Shen
  • Patent number: 4198413
    Abstract: Derivatives of .alpha.-methyl-3,4-dihydroxyphenylalanine which are useful in compositions as anti-hypertensive agents.
    Type: Grant
    Filed: July 6, 1978
    Date of Patent: April 15, 1980
    Assignee: Merck & Co., Inc.
    Inventor: Walfred S. Saari
  • Patent number: 4198513
    Abstract: Triazoles substituted at the 3 and 5 positions having an optional substituent in the 1 position are provided. Methods of preparing the novel substituted triazoles are described. The substituted triazoles are useful as anti-gout and anti-hyperuricemic agents. Compositions useful in the treatment of gout and hyperuricemia containing a substituted triazole as the active ingredient are also provided.
    Type: Grant
    Filed: April 7, 1978
    Date of Patent: April 15, 1980
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Frederick C. Novello
  • Patent number: 4195023
    Abstract: Certain novel acyl saccharins and acyl 3-oxo-1,2-benzisothiazolines, their preparation, pharmaceutical compositions and novel methods of inhibiting elatase and treating emphysema are disclosed.
    Type: Grant
    Filed: August 20, 1975
    Date of Patent: March 25, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Dennis Mulvey, Howard Jones, Morris Zimmerman
  • Patent number: 4191754
    Abstract: Bicyclic somatostatin analogs and pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by a combination of the solid phase method and the solution method. These analogs have the property of inhibiting the release of insulin, glucagon and growth hormone in humans and animals. The compounds are particularly useful in the treatment of diabetes. Due to the bicyclic structure, these analogs are resistant to enzymatic metabolism and have a longer duration of activity.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: March 4, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Daniel F. Veber, Ruth F. Nutt
  • Patent number: 4190655
    Abstract: A novel salt of amiloride particularly amiloride citrate has been discovered. Because of its inherent insolubility and less bitter taste, it would lend itself to be more easily formulated into oral liquids, sustained release formulations and chewable tablets than would amiloride hydrochloride.
    Type: Grant
    Filed: August 28, 1978
    Date of Patent: February 26, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Joseph DeMarco, Gerald S. Brenner
  • Patent number: 4189496
    Abstract: 2,3-Dihydro-6,7-disubstituted-5-thienylmethyl or furylmethyl benzofuran-2-carboxylic acids, the pharmaceutically acceptable salt, ester and amide derivatives thereof are disclosed having diuretic-saluretic, uricosuric and antihypertensive activity.
    Type: Grant
    Filed: February 16, 1978
    Date of Patent: February 19, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., William F. Hoffman, Otto W. Woltersdorf, Jr.
  • Patent number: 4187315
    Abstract: N-Alkyl and N-cycloalkyloxamic acid derivatives are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate urolithiasis (kidney and bladder stone disease).
    Type: Grant
    Filed: October 11, 1978
    Date of Patent: February 5, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Frederick C. Novello, Walfred S. Saari
  • Patent number: 4185088
    Abstract: The invention disclosed herein relates to novel non-adhesive, free-flowing, pharmacologically acceptable compositions comprising ionene quaternary polymers effective as bile acid sequestrants, such as poly-[{methyl-(3-trimethylammoniopropyl)iminio}trimethylene dichloride], adsorbed on a pulverulent, solid aggregate of large surface to mass ratio, such as fumed silicas and silica aerogels. It also relates to the novel process for preparing such adsorbate compositions which comprises forming a substantially, uniform suspension of the finely-divided solid aggregate in an aqueous solution of poly-[{methyl-(3-trimethylammoniopropyl)iminio}trimethylene dichloride], evaporatively removing the water from the suspension, and drying the adsorbate thus produced.
    Type: Grant
    Filed: October 19, 1978
    Date of Patent: January 22, 1980
    Assignee: Merck & Co., Inc.
    Inventor: Arthur F. Wagner
  • Patent number: 4181691
    Abstract: The invention relates to an improved U-shaped splash bar fill configuration for use in crossflow cooling towers.
    Type: Grant
    Filed: November 13, 1978
    Date of Patent: January 1, 1980
    Assignee: Baltimore Aircoil Company, Inc.
    Inventors: Robert E. Cates, Edward N. Schinner
  • Patent number: 4178374
    Abstract: Compositions containing substituted 1,2,5 thiadiazole .beta.-blocking agent and pyrazine and/or thiazide diuretic, and a method of treating hypertensive animals are disclosed.
    Type: Grant
    Filed: April 10, 1978
    Date of Patent: December 11, 1979
    Assignee: Merck & Co., Inc.
    Inventor: Charles S. Sweet
  • Patent number: 4178386
    Abstract: 2-Hydroxy-3-butynoic acid is disclosed which inhibits glycolic acid oxidase and thus is useful in the treatment and prevention of calcium oxalate urolithiasis (calcium oxylate kidney and bladder stone disease).
    Type: Grant
    Filed: October 11, 1978
    Date of Patent: December 11, 1979
    Assignee: Merck & Co., Inc.
    Inventors: Haydn W. R. Williams, Edward J. Cragoe, Jr., Clarence S. Rooney
  • Patent number: 4176187
    Abstract: Dihydropyridine ureas having antihypertensive activity are disclosed.
    Type: Grant
    Filed: June 29, 1978
    Date of Patent: November 27, 1979
    Assignee: Merck & Co., Inc.
    Inventors: William V. Ruyle, Michael H. Fisher